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Abstract 
Background: S-Adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) are relevant to a variety of diseases. 
Previous reports that quantified SAM and SAH were based on HPLC or LC–MS/MS. No antibody against SAM has been 
generated, and the antibody against SAH cannot be used with blood samples. Immunoassays have not been used to 
measure SAM and SAH. In this study, ELISA was used to measure blood SAM and SAH levels.
Results: Specific antibodies against SAM were produced for the first time using a stable analog as the antigen. The 
monoclonal antibodies against SAM and SAH were characterized. No cross-reactivity was detected for the analyzed 
analogs. For the anti-SAM antibodies, the ELISA sensitivity was ~2 nM, and the affinity was 7.29 × 1010 L/mol. For the 
anti-SAH antibodies, the sensitivity was ~15 nM, and the affinity was 2.79 × 108 L/mol. Using high-quality antibod-
ies against SAM and SAH, immunoassays for the detection of SAM and SAH levels in blood and tissue samples were 
developed. Clinical investigations using immunoassays to measure SAM, SAH and the methylation index (MI) in nor-
mal and diseased samples indicated that (1) the SAM level is age and gender dependent; (2) the SAM level is associ-
ated with the severity of liver diseases, inflammatory reactions and other diseases; and (3) the methylation index (MI) 
is significantly reduced in many diseases and may serve as a screening biomarker to identify potentially unfavorable 
health conditions.
Conclusion: It is possible to generate antibodies against active small biomolecules with weak immunogenicity, such 
as SAM and SAH, using traditional hybridoma technology. The antigens and antibodies described here will contribute 
to the development of immunoassays to measure SAM, SAH and related molecules. These assays enable the MI to be 
measured specifically, accurately, easily and quickly without costly equipment. This preliminary study indicates that 
the MI could be an effective indicator of general health, except under conditions that may alter the value of the MI, 
such as special diets and medications.
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Background
S-Adenosylmethionine (SAM, SAMe, or AdoMet) is a 
naturally occurring compound found in all living cells. 
SAM is a critical metabolite derived from adenosine 
triphosphate (ATP) and methionine (Met) via methio-
nine adenosyltransferase (MAT EC2.5.1.6). SAM is an 
essential, metabolically pleiotropic molecule that partici-
pates in multiple cellular reactions as the precursor for 
the synthesis of glutathione and the major methyl donor 
for the methylation of nucleic acids, phospholipids, 
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histones, biogenic amines, and proteins. SAM is the key 
molecule in the Met cycle and plays important roles in 
transmethylation, transsulfuration and aminopropyla-
tion. Methylation processes are the central biochemical 
basis of the neuropsychiatry of folate and B12 metabo-
lism. The de novo synthesis of Met requires vitamin 
B12, which is involved directly in the transfer of the 
methyl group to homocysteine (HCys). Deficiency in 
either vitamin B12 or folate is considered the cause of 
low methylation index (MI). Metabolic hypomethyla-
tion might be one mechanism related to adverse clinical 
outcomes in B12-deficient individuals [1]. SAM provides 
the methyl group during the production of essential bio-
molecules such as carnitine (fat burner), acetyl-l-carni-
tine (neuro-nutrient, membrane-transporting agent), 
phosphocreatine (primary ATP reservoir), epinephrine/
adrenalin (endogenous catecholamine, stress hormone 
and neurotransmitter), phosphatidylcholine (the most 
important membrane phospholipid), and melatonin (cir-
cadian rhythm modulator). Combined administration of 
N-acetyl cysteine (an antioxidant and glutathione pre-
cursor that protects against Abeta neurotoxicity), acetyl-
l-carnitine (increases ATP levels, protects mitochondria, 
and buffers Abeta neurotoxicity), and S-adenosylmethio-
nine (facilitates glutathione usage and maintains acetyl-
choline levels) enhances or maintains cognitive function 
and attenuates or prevents aggression, in mouse models 
of aging and neurodegeneration. Treatment with this 
nutraceutical combination can compensate for a lack of 
dietary folate and vitamin E [2]. Transsulfuration begins 
with SAH, the residual structure of SAM after donat-
ing the methyl group (trans-methylation). Hydrolysis of 
SAH yields HCys, which is converted to cystathionine, 
cysteine, and then glutathione, the hepatocellular antiox-
idant and life-saving detoxification agent. Aminopropyla-
tion is another process that is initiated by SAM through 
decarboxylation. Decarboxylated SAM is coupled to 
putrescine to generate spermidine and spermine, which 
are critical for cell growth, differentiation and DNA and 
RNA stability. Methylthioadenosine (MTA), the by-prod-
uct of polyamine synthesis, is a powerful analgesic and 
anti-inflammatory agent that may be responsible for the 
clinical benefits observed in the treatment of osteoarthri-
tis, rheumatoid arthritis and fibromyalgia with SAM [3, 
4].
Defects in methylation lead to cell dysfunction and 
accompanying changes in SAM levels. Poor methylation 
or SAM deficiency has been implicated or related to the 
development of birth defects [5], cardiovascular disease 
[6], cancers [7], liver disease [8], and many other diseases 
[9–14, 18, 20, 21]. SAM levels have been identified as a 
diagnostic marker for Pneumocystis carinii pneumonia 
(PCP) in patients with immune-compromised conditions 
[15]. SAM has been used clinically for the treatment of 
liver disease, arthritis [16], and depression [17]. SAM 
produced cognitive improvement in patients with Alz-
heimer’s disease [19]. Treatment with SAM has been 
confirmed to be as effective as prescription tricyclic anti-
depressants [22] and non-steroidal anti-inflammatory 
drugs (NSAIDS) [3], with efficacy for the treatment of 
some liver conditions, such as cholestasis in pregnancy 
and intrahepatic cholestasis associated with liver diseases 
[23, 24]. More significantly, SAM is well tolerated, and no 
serious side effects have been observed. SAM provides 
rapid relief and is superior to tricyclic antidepressant 
treatment [25].
A deficiency of the major dietary sources of methyl 
donors, Met and choline, leads to the formation of liver 
cancer in rodents [26]. Extra-hepatic tumor formation 
increased in carcinogen-treated animals fed diets low 
in methyl donors including Met, choline, and folic acid 
[27]. Several mechanisms explain the enhancing effects 
of dietary methyl deprivation on carcinogenesis [28], of 
which the most accepted is that dietary methyl deficiency 
results in abnormal DNA methylation [29]. A critical 
metabolite in this hypothesis is SAM, the sole methyl 
donor in the body. Studies have linked deficiencies in 
folic acid, vitamin B12, and Met with an increased risk 
of cancer in various organs [30]. The question thus arises 
whether such deficiencies exert their activities through 
diminished availability of SAM. Studies have also demon-
strated the utility of determining erythrocyte SAM and 
SAH and of plasma HCys in assessing disease status [31].
Due to the importance of SAM and SAH, an easy 
and reliable method is needed to measure their con-
centrations in a biological sample. A classic method for 
measuring SAM and SAH in rat liver utilizes the trip-
olyphosphatase activity associated with SAM synthetase 
in rat liver [32]. Tripolyphosphatase activity is stimulated 
by low concentrations of SAM [33]. The reported sensi-
tivity of this method is 0.1 nmol of SAM in an assay vol-
ume of 0.1 mL (i.e., 10−6 M). The samples are lyophilized, 
homogenized in acid, and centrifuged. The supernatant 
is then passed through Dowex 1 to remove endogenous 
inorganic phosphate and other potential interferons in 
the tissue. Great care is needed to avoid inorganic phos-
phate contamination from all reagents, including the 
enzyme preparation and glassware. The disadvantages 
of this assay are a clear lack of specificity, low sensitiv-
ity (1  µM), and difficulties related to controls and com-
parisons among assays in different laboratories. Another 
common method for measuring SAM in tissues or bio-
logical fluids is HPLC or electrophoresis after sample 
preparation, which normally comprises protein precipi-
tation and/or extraction [34]. Post-column detection 
may include derivatization followed by measurement 
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by absorption, fluorescence, or electrochemical changes 
and, more recently, by LC–MS/MS [35]. These methods 
are laborious, time-consuming and require expensive 
equipment. LC–MS/MS does not consider the biologi-
cal relevance of the detected metabolites. Therefore, the 
use of LC–MS/MS to measure SAM and SAH may not 
be accurate or complete from a biological perspective. 
Chemical methods can only detect the free form of SAM 
or SAH at the time of sample collection and exclude any 
SAM or SAH associated with other biomolecules. The 
inability of LC–MS/MS to detect SAM molecules that 
fall within the specific molecular weight range defined by 
LC–MS/MS in a sample does not indicate that SAM has 
been completely degraded, lost or is not functional. Fur-
thermore, the SAM standard used to train LC–MS/MS 
is not identical to SAM from living cells. However, for a 
technology such as LC–MS/MS, a molecule identical to 
the molecule of interest is required as the training stand-
ard. Recent studies have suggested that GC–MS and 
LC–MS analytical methods may not accurately meas-
ure metabolites due to changes caused by lengthy and 
high-temperature manipulation processes during sample 
extraction, preprocessing and measurement [36].
SAM is an intrinsically unstable molecule, and its opti-
cal density maximum of 258–260 nm is not unique. Thus, 
the determination of the concentration of SAM in vari-
ous biological fluids and tissues is a challenging task. A 
simple, convenient method that does not require costly 
instrumentation is clearly desirable for determining the 
biological concentration of SAM and monitoring changes 
in SAM levels in body fluids, tissues and organelles. The 
MI is defined as the ratio of the concentration of SAM 
to the concentration of SAH. Given the important roles 
of SAM and SAH in various pathological processes, it 
is desirable to conveniently measure the levels of SAM 
and SAH using methods that can be performed in typi-
cal research and clinical laboratories. The availability of 
specific antibodies against SAM and SAH has enabled 
the development of various forms of immunoassays to 
satisfy different needs. In this study, the generation and 
characterization of anti-SAM and anti-SAH antibodies as 
well as their applications are described. The usefulness of 
blood SAM and MI as markers for evaluating the roles 
of SAM in the onset and development of human diseases 
was also evaluated. This investigation included the deter-
mination of SAM, SAH, and MI in blood samples col-
lected from normal and diseased subjects.
Methods
The hapten used to generate anti‑SAM antibodies
Many SAM analogs were synthesized as shown in US pat-
ent No. 8,344,115 and evaluated to identify the best analog 
to generate the best anti-SAM antibodies. One of the 
most promising analogs, 5′-N-methyl, 5′-N-butyryl-5′-
deoxyadenosine, or 5′-((3-carboxypropyl)methylamino)- 
5′-deoxy-adenosine, abbreviated as aza-deamino-SAM 
or shortened as aza-SAM, was employed to  immunize 
Balb/c mice. All asymmetric carbons in aza-SAM main-
tained their chirality.
Preparation of KLH‑aza‑SAM
To a flask containing 15  mg of aza-SAM that was vac-
uum-dried overnight, appropriate amounts (proportional 
to aza-SAM) of DCC (N,N′-dicyclohexylcarbodiimide), 
NHS (N-hydroxysuccinimide) and KLH (keyhole limpet 
hemocyanin) were added. Approximately 1.5  mL of dry 
DMF (dimethylformamide) was then added to the flask. 
The solution was stirred at room temperature. Formation 
of the NHS ester was confirmed by thin layer chromatog-
raphy. The final volume after dialysis was 29.5 mL with a 
concentration of 0.6 mg/mL.
Preparation of PLL‑aza‑SAM (poly‑l‑lysine‑conjugated 
aza‑SAM)
A 4.72-mg quantity of aza-SAM was dissolved in 1  mL 
of DMF with 6.5 mg EDC (1-ethyl-3-(3-dimethylamino-
propyl) carbodiimide. Next, HCl and 4 mg of NHS were 
added, followed by stirring at room temperature in the 
dark overnight. Then, 1.5  mg of PLL was dissolved in 
1 mL of 10 mM PBS pH 8.2. Aza-SAM was then added 
slowly to the PLL solution, and the mixture was incu-
bated overnight in the dark. The reaction mixture was 
dialyzed for 48 h against 10 mM PBS, pH 7.3.
Preparation of BSA‑SAH
A 3.8-mg quantity of SAH (Sigma) was dissolved in 
1.5  mL of PBS. Then, 10  mg of EDC HCl (Sigma) and 
4.5 mg of NHS were added, and the mixture was stirred at 
room temperature for 24 h. We then dissolved 12.9 mg of 
BSA in PBS. The SAH was added to the BSA solution, and 
the mixture was incubated at 4 °C in the dark overnight.
Preparation of HRP‑conjugated antibodies
To develop a more efficient ELISA, HRP (horseradish 
peroxidase, Sigma) was directly conjugated to mouse 
anti-SAM and mouse anti-SAH antibodies. Five mil-
ligrams of HRP (dissolved in deionized water at 10 mg/
mL) was added to 0.5  mL of freshly prepared 0.06  M 
sodium periodate and incubated at 4  °C for 30  min. 
Approximately 5 mg of antibody was added to the HRP 
solution and dialyzed overnight against 50 mM carbonate 
buffer, pH 9.6. Approximately 2  mg of sodium borohy-
dride was added to the reaction mixture and incubated in 
the dark at 4 °C for 2 h with shaking once every 30 min. 
The sample was then dialyzed against 0.01  M PBS, pH 
7.2, for at least 18 h.
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Procedures for generating monoclonal antibodies 
against SAM and SAH
Mouse monoclonal antibodies were produced based on 
procedures developed in a previous work [37]. Immu-
nization was performed via subcutaneous injection of 
0.1  mg of antigen at multiple sites into Balb/c mice. The 
initial injection consisted of a 1:1 mixture of complete Fre-
und’s adjuvant and aza-SAM-KLH or SAH-BSA conjugate 
solutions in PBS upon emulsification. The subsequent 3 
injections were similar except for the use of incomplete 
Freund’s adjuvant. Blood was collected from each immu-
nized mouse at 1–2  weeks. The obtained antisera were 
then evaluated to determine the immune response and the 
antibody titer. Mice with satisfactory titers were primed 
via intravenous injection with immunogen three days prior 
to its sacrifice. The spleens of the mice were harvested and 
homogenized. The spleen cells were then fused with mye-
loma SP2/0 cells, and the fused cell suspension was plated 
out in 96-well microtiter plates. Hybridomas were grown 
in RPMI 1640 medium enriched with 18% fetal bovine 
serum, HAT and HT supplements and then screened. 
Clones that were positive for SAM or SAH were selected 
for further studies, including cross-reactivity tests. After 
the clones were obtained, the cells were injected into mice 
for ascite production. The antibody was then purified from 
the ascites using a protein A affinity column.
Methionine adenosyltransferase (MAT)‑catalyzed SAM 
biosynthesis
Solutions of 1 mM ATP and L-Met (Sigma) were prepared 
in 100  mM Tris, 100  mM KCl, 20  mM MgSO4, and 1% 
ProClin, pH 7.42. Recombinant E. coli MAT was added to 
the above substrates at a concentration of 0.6 mg/mL or 
1 mg/mL, respectively. The reaction mixture was analyzed 
in duplicate using the SAM cELISA described in this sec-
tion. The synthesized SAM was measured every 10  min 
after incubation at 37 °C for 20–80 min.
Blood sample collection
Informed consent for sample collection and publication 
of clinical data was obtained from the participants. Sera 
were obtained from 81 normal volunteers, 310 plasma 
samples from the Changsha Blood Center and sera from 
505 patients. For the plasma samples, peripheral venous 
blood was collected in tubes with EDTA and mixed well. 
The tubes were immediately cooled to 4  °C and centri-
fuged at 2000 g or higher for 15 min within 30 min after 
blood collection to obtain plasma. The plasma was either 
used for the measurements or frozen at −20 °C for future 
use. Serum samples were collected in serum separating 
tubes and placed in the refrigerator for approximately 2 h 
until blood coagulation occurred. The remaining steps 
were similar to those used for plasma collection. Plasma 
from the blood center was stored in the refrigerator for 
1–7 h before centrifugation and freezing.
The Supplemental Data (Additional file  1) provides 
details regarding disease information. Patient samples 
were collected from clinical laboratories with no further 
information about the patient and disease conditions, sta-
tus and treatments. Statistical analyses were performed 
using R by Dr. Huaitian Liu (National Cancer Institute, 
National Institute of Health, Rockville, MD) and Sydney 
Wong (University of California, Berkeley, CA).
Competitive ELISA (cELISA)
To quantify plasma SAM and SAH levels, direct cELISA 
was developed by immobilizing antigens to a solid plate 
first, followed by the addition of SAM or SAH and HRP-
labeled anti-SAM or anti-SAH antibodies. Antigens from 
a sample or standards competed with the correspond-
ing fixed amount of immobilized antigens for binding to 
specific HRP-labeled antibodies. The final HRP substrate 
absorption values at 450  nM were inversely propor-
tional to the amount of detected antigen, i.e., the higher 
the OD450 value, the lower the level of SAM or SAH in 
a sample. The wells of a 96-well ELISA plate (Corning 
high-affinity strips for ELISA) were coated with 0.05 μg/
mL PLL-aza-SAM or 0.5 μg/mL BSA-SAH at 4  °C over-
night. A series of SAM or SAH standards (aza-SAM from 
0 to 960 nM and SAH-Na from 0 to 100 nM) and samples 
were added, followed by a 1:30,000 dilution of HRP-anti-
SAM to a final volume of 100 μl. The plate was sealed and 
incubated at 37 °C for 60 min. The plate was then washed 
3 times with PBST (10  mM PB, 150  mM NaCl, pH 7.4, 
0.1% Tween 20). TMB (3,3′,5,5′-tetramethylbenzidine) 
was added to the wells (InnoReagents), and the plate was 
sealed and incubated for 15  min at 37  °C. The reaction 
was then stopped, and the OD450 values were read using 
a Multiskan FC reader (Thermo Fisher). The standards 
were generated using heat-inactivated pooled normal 
human plasma to minimize the matrix effect.
Other materials




Characterization of the anti‑SAM monoclonal antibodies 
118‑6 and 84‑3
A good and useful antibody should have high specific-
ity, sensitivity and affinity. The best way to demonstrate 
that the newly developed anti-SAM antibody specifi-
cally binds to SAM is to confirm that the anti-SAM 
antibody can bind to in  vitro-synthesized SAM iden-
tical to the SAM synthesized in living cells. Figure  1 
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shows that the amount of SAM synthesized increased 
with a longer reaction time but reached a maximum 
after 60  min. This result indicates that the product of 
Met catalysis of ATP and Met was able to competitively 
bind the anti-SAM antibody. Dosage-dependent com-
petition was detected as the sample was added to the 
cELISA system; SAM from the sample competed with 
the coated SAM hapten to bind the HRP-conjugated 
antibody 118-6. The sample consisted of Met, ATP and 
MAT in 100  mM Tris, 100  mM KCl, 50  mM MgCl2, 
pH 7.42, and 1% ProClin. The results indicated that the 
developed anti-SAM all specifically bind to physiologi-
cally produced SAM. The system permits simultaneous 
MAT-catalyzed SAM synthesis and SAM immunoas-
say, thus ensuring the accuracy of the results because 
SAM is unstable and termination of the MAT catalytic 
reaction at a precise time point is difficult. The use of 
cELISA to directly measure SAM in this scenario has 
even more important advantages for two reasons: (a) 
following synthesis, SAM remains associated with 
MAT for a period of time before release, and the tra-
ditional HPLC and MS methods for measuring SAM 
are unable to measure SAM in the MAT-SAM com-
plex; (b) the preprocessing steps for HPLC and MS 
inevitably cause some SAM decomposition, leading 
to inaccurate results. The results in Fig. 2 indicate not 
only that the naturally produced SAM can compete in 
a dose-dependent manner with the SAM or aza-SAM 
coated onto the microtiter plates in terms of anti-SAM 
antibody binding but also that the method is a quick, 
easy and accurate way to measure the enzymatic activ-
ity of MAT. Thus, anti-SAM antibodies can be used to 
accurately measure MAT activity.
Cross-reactivity with SAM analogs was tested using up 
to 100-fold higher dosages of analogs than that of SAM 
antigen with the established cELISA method. Figure  2 
shows a cELISA using the anti-SAM monoclonal anti-
body 118-6. In this assay, 0.1  µg/mL PLL-aza-SAM was 
used to coat a 96-well plate. Serial dilutions of Aza-SAM, 
SAH, adenosine, L-Met, ADP (adenosine diphosphate), 
ATP, MTA and 1:35,000 of 118-6 antibody were added. 
HRP-conjugated goat anti-mouse IgG antibody and TMB 
substrate were used to develop the results. The cross-
reactivity of antibody 84-3 was similar to that of 118-6. 
At concentrations exceeding 10  μM Met, SAH, MTA, 
adenosine, ADP, and ATP, competition for the coated 
antigen (PLL-aza-SAM) with the HRP-antibody did not 
occur (data not shown). No competitive inhibition of the 
HRP signal was observed using these analogs, whereas 
inhibition was clearly evident when SAM was added at a 
much lower dosage than the analogs. These data indicate 
that the cross-reactivity of all analogs was <1%.
When the antibodies were adjusted to 1 mg/mL in an 
indirect ELISA assay, the titer of the anti-SAM monoclo-
nal antibodies ranged from 1:10,000 to 1:100,000 depend-
ing on the criteria and conditions used.
Fig. 1 Detection of SAM synthesized from Met and ATP as substrates 
by the MAT-catalyzed reaction over time. The cELISA was used to 
measure SAM. The samples for the cELISA were the product of the fol-
lowing biochemical reaction. MAT was added to a maximum of 2 mM 
Met and ATP in the buffer described in the Methods at 37 °C. The 
biochemical reaction and ELISA were performed simultaneously and 
then stopped at 20, 30, 40, 50, 60, 70 and 80 min after the reaction. 
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Fig. 2 Cross-reactivity of the mouse anti-SAM monoclonal antibody 
118-6 with SAM analogs. Each well of a 96-well plate was coated with 
0.1 µg/mL PLL-aza-SAM, and serial dilutions of the SAM standard aza-
SAM, S-adenosylhomocysteine (SAH), adenosine (Ade), L-methionine 
(Met), methylthioadenosine (MTA), adenosine diphosphate (ADP), 
and adenosine triphosphate (ATP) and 1:35,000 antibody were added. 
HRP-conjugated goat anti-mouse IgG antibody and substrate TMB 
were then added. The y-axis shows the OD450 of each well in rela-
tion to the wells without antigen competition. The x-axis shows the 
concentration of SAM. A lower value on the y-axis indicates greater 
competition
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To demonstrate the ease and affinity of antigen and 
antibody binding, ELISA assays were performed using 
different amounts of coated antigens. For the anti-SAM 
clone 118-6, when antigen was coated at a higher con-
centration of 0.2 μg/mL, half the maximum OD was 
obtained at a dilution of 1:54,800. The corresponding 
antibody concentration was (Ab) = (1 mg mL−1/160,000 
g mol−1)/54,800 = 1.14 × 10−10 M, where 160,000 is the 
molecular weight of the antibody. When the coating anti-
gen concentration was less than 0.1 μg/mL, half the max-
imum OD was observed at 1:44,300. The corresponding 
antibody concentration was (Ab)t = (1 mg mL−1/160,000 
g mol−1)/44,300 = 1.41 × 10−10 M, where n = 0.2/0.1(μg/
mL) =  2, Ka =  (n −  1)/2*(n(Ab) −  (Ab)t) =  5.75 ×  10
9 L/mol  =  1.74  ×  10−10 M. For clone 84-3, when the 
coating antigen was 0.1 μg/mL, half the maximum OD 
was observed at approximately 1:13,0000. When the 
coating antigen was 0.05 μg/mL, half the maximum OD 
was detected when 84-3 was diluted at approximately 
1:70,000. Using the same method as above, Ka = (n − 1)/
2*(n[Ab] − [Ab]t) = 7.29 × 1010 L/mol = 1.37 × 10−11 M.
Tables  1, 2 shows the results of a SAM cELISA using 
three different coating amounts of PLL-aza-SAM when 
mouse anti-SAM antibody 84-3 was used at a dilution of 
1:35,000 and from one coating plate when antibody 118-6 
was tested in indirect cELISA assays. Different amounts 
of coating antigen, antibody, and buffer provide slightly 
different minimum detection limits. The data in Table  1 
demonstrate that the minimum detection limits were 
between 1.6 and 3  nM when antibody 84-3 was used, 
depending on the coating antigens (see Table 1; Fig. 3a), 
and 7.8 nM when antibody 118-6 was used at a dilution 
of 1:32,000 (see Table 2; Fig. 3b). These values were esti-
mated from the corresponding concentrations calculated 
from the standard curve equation given the OD450, that 
is, the average of the OD450 minus twice the standard 
deviation (SD) of the blank wells (without antigen). When 
the same amount of coating antigen (0.1 µg/mL) was used, 
antibody 84-3 exhibited higher sensitivity than antibody 
118-6, consistent with the greater binding affinity of 84-3 
compared with 118-6. The single-digit nM sensitivity indi-
cates great potential in applications evaluating these criti-
cal metabolites under various conditions. Because SAM 
levels decreased under pathological conditions, it will be 
very important to obtain antibodies that are sufficiently 
sensitive to measure the low levels of SAM in samples.
Characterization of the anti‑SAH monoclonal antibody 301‑1
The antibody specificity was evaluated by examining 
the cross-reactivity of 301-1 with SAH analogs. Figure 4 
shows a cELISA using 301-1. A BSA-SAH concentration 
of 0.5 µg/mL was coated in each well of a 96-well plate. 
Serial dilutions of the SAH standard (SAHNa), S-aden-
osylmethionine (SAM4: Sigma Cat# A2408, SAM1: 
aza-SAM), HCys, l-cysteine (L-Cys), adenosine (Ade), 
glutathione (GST), L-cystathionine (L-CTT), MTA, ADP, 
ATP and properly diluted 301-1 were added. The cross-
reactivity was approximately 1.5% with SAM, approxi-
mately 5% with MTA, and <1% with all other analogs. 
The relatively higher cross-reactivity with SAM and 
MTA (<5%) is not a concern because the physiological 
levels of SAM and MTA are much lower than 1  µM, a 
level at which no cross-reactivity with the antibody was 
observed.
Table 1 OD450 measured using different amounts of coating antigens with antibody 84-3
a Sensitivity was estimated by the corresponding concentration calculated from standard curve equation given the OD450 (=OD450 at zero antigen − 2 × standard 
deviation of blank wells). ELISA was performed in triplicates. Mouse anti-SAM antibody 84-3 was used at 1:35,000
SAM standard (nM) 0.2 µg/mL PLL‑aza‑SAM 0.15 µg/mL 0.1 µg/mL
Blank 0.0498 0.056 0.0522 0.0476 0.0471 0.0482 0.0754 0.0515 0.0476
0 1.4709 1.4344 1.4072 1.215 1.2484 1.2651 1.0844 1.1231 1.0633
6.3 1.365 1.3257 1.2673 1.0789 1.0734 1.0842 0.879 0.9122 0.8995
25 1.1769 1.1498 1.1015 0.8231 0.844 0.8334 0.6209 0.6561 0.6679
50 1.0230 0.9856 0.9577 0.6428 0.6362 0.6005 0.4517 0.4555 0.5187
100 0.7687 0.7532 0.7292 0.4292 0.4203 0.4427 0.3036 0.3103 0.3071
Sensitivitya 3.0 nM 1.7 nM 1.6 nM
Table 2 Sensitivity of mouse anti-SAM antibody 118-6
a Sensitivity was estimated by the corresponding concentration calculated 
from standard curve given the OD 450 (=OD450 at zero antigen – 2 × standard 
deviation of blank wells). ELISA was performed in triplicates. PLL-aza-SAM was 
coated at 0.1 µg/mL and the 118-6 used at 1:32,000
SAM standard (nM) OD450 OD450 OD450 Mean SD
Blank 0.0556 0.0808 0.0616 0.0660 0.0131
0 1.2189 1.2831 1.3030 1.2683 0.0439
6.3 1.110 1.0648 0.9757 1.0502 0.0683
12.5 0.885 0.8004 0.8737 0.8530 0.0459
25 0.6252 0.6435 0.6108 0.6265 0.0164
50 0.3838 0.3995 0.3782 0.3872 0.0110
Sensitivitya 2.6 nM
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Using the same method described above for affinity, 
when the coating antigen was 1 μg/mL, half the maximum 
OD was observed at a dilution of 1:1900. When the coat-
ing antigen was 0.5 μg/mL, half of the maximum OD was 
observed at approximately 1:1100. Thus, Ka = (n − 1)/2* 
(n[Ab] − [Ab]t) = 2.79 × 108 L/mol = 3.6 × 10−9 M. The 
titer of 301-1 was in the range of 1:4000–8000 when the 
antibodies were adjusted to a concentration of 1 mg/mL 
in an indirect ELISA assay.
Table  3 shows the cELISA results for 0.5 μg/mL BSA-
SAH coated onto a microtiter plate with mouse anti-301-1 
at a dilution of 1:1000. Different amounts of coating anti-
gen, antibody, and incubating buffer may provide slightly 
different minimum detection limits. The same method 
described above was used to calculate the minimum 
detection limit, which was approximately 15.6 nM.
cELISA
The standard curves for cELISA of SAM and SAH are 
shown in Figs.  5a, b, respectively. LOGIT =  Ln(A/AS0/
(1 −  A/AS0)), where A is the OD450 value of a sample 
or the standard and AS0 is the OD450 value of the con-
trol (without antigen). A negative LOGIT value indi-
cates that A/AS0 is less than 50% and the inhibition rate 
(1  −  A/AS0) is greater than 50%. As shown in Fig.  5a, 
the standard curves were very similar when different 
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Fig. 3 Standard curves for the mouse monoclonal antibody against 
SAM in the sensitivity tests. a Using antibody 84-3 at 1:35,000 with 
different amounts of coating antigens (0.1, 0.15, and 0.2 µg/mL) in 
an indirect cELISA. b Using antibody 118-6 at 1:32,000 with coating 
antigen at 0.1 µg/mL in an indirect cELISA. The x-axis shows the 
values of the base 10 logarithm of the standard concentrations. The 
y-axis is expressed as LOGIT, which is defined as Ln(A/AS0/(1 − A/AS0)), 
where A is the OD450 value of the standard and AS0 is the OD450 





























Fig. 4 Cross-reactivity of the mouse anti-S-adenosylhomocysteine 
monoclonal antibody 301-1 with SAH analogs. Each well of a 96-well 
plate was coated with 0.5 µg/mL BSA-SAH. Serial dilutions of SAH 
standard (SAH sodium, SAH-Na), S-adenosylmethionine (SAM4: from 
Sigma-Aldrich Cat# A2408, SAM1: aza-SAM), homocysteine (H-Cys), 
l-cysteine (L-Cys), adenosine (Ade), glutathione (GST), L-cystathionine 
(L-CTT), methylthioadenosine (MTA), ADP (adenosine diphosphate), 
ATP (adenosine triphosphate) and properly diluted 301-1 were added. 
HRP-conjugated goat anti-mouse IgG antibody and TMB substrate 
were added to develop the color, and the OD450 was measured. The 
y-axis shows the OD450 for each test. The x-axis shows the concentra-
tion of SAH. A lower OD450 value indicates greater competition
Table 3 SAH standard curve and  sensitivity of  antibody 
301-1
a Sensitivity was estimated by the corresponding concentration calculated 
from standard curve given the OD 450 (=OD450 at zero antigen – 2 × standard 
deviation of blank wells). ELISA was performed in triplicates. BSA-SAH was 
coated at 0.5 µg/mL and mouse anti-SAH antibody 301-1 was used at 1:2000
SAH (nM) OD450 OD450 OD450 Mean SD
250 0.4116 0.4426 0.442 0.4321 0.0177
125 0.5421 0.6358 0.5372 0.5717 0.0555
62.5 0.6055 0.7115 0.6444 0.6538 0.0536
31.3 0.7285 0.8199 0.7545 0.7676 0.0471
15.6 0.8045 0.8273 0.7975 0.8098 0.0156
7.8 0.7602 0.8113 0.7708 0.7808 0.0270
3.9 0.7722 0.9144 0.7786 0.8217 0.0803
0 0.8770 0.8992 0.8329 0.8697 0.0337
Sensitivitya ~15.6 nM
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1:22,000 and 1:32,000 were used. As shown in Fig.  5b, 
different batches of HRP-anti-SAH antibody 301-3 pro-
vided slightly different competitive inhibition results, 
with Lot# 5 exhibiting greater inhibition. Competitive 
inhibition results in reduced OD450 readings from TMB 
substrates due to the addition of a high dosage of free 
SAM or aza-SAM, allowing less coated PLL-aza-SAM 
to bind to the HRP-anti-SAM antibody. After washing 
the microtiter plate, less HRP-anti-SAM remained on 
the plate, and thus the weaker OD450 was equivalent 
to an inhibitory effect. As shown in Fig. 5a, a significant 
portion of the SAM standard curve was within the nega-
tive portion of the y-axis (LOGIT). A negative LOGIT 
indicates competitive inhibition exceeding 50%. For the 
SAH standard curve, as represented in Fig.  5b, a small 
portion of the SAH standard curve was within the nega-
tive LOGIT. Therefore, the inhibition rate is much higher 
in SAM cELISA than in SAH cELISA, which is partly 
determined by differences in the affinity of the anti-SAM 
and anti-SAH antibodies.
SAH is normally low in humans, and thus the ability 
to measure low levels of SAH is essential. The sensitivi-
ties of the anti-SAM and anti-SAH antibodies reported 
herein are the best to date. Using direct cELISA, the 
minimum detection limit was approximately 2  nM for 
SAM and 15 nM for SAH. Other more sensitive immu-
nological technologies can be developed to further 
reduce the minimum detection limit, increase the range 
of detection, or improve the assays via faster, easier and 
higher throughput and better quality control and preci-
sion. Sensitivity is essential for most IVD (in vitro diag-
nosis) applications.
SAH is metabolically linked to SAM, and the structure 
of SAH contains one less carbon (a methyl group) than 
SAM. The co-existence and structural similarity of SAM 
and SAH present a great challenge in the development 
of a method for the specific determination of the con-
centration of either molecule in a biological sample. The 
unstable nature of SAM further complicates its determi-
nation. As the immediate precursor of HCys produced 
in the body, SAH has recently been suggested to be a 
more sensitive indicator of the risk of vascular diseases 
than plasma HCys [38]. The total plasma concentration 
of SAH is normally much lower than that of HCys. As 
with SAM, SAH has no distinct absorption characteris-
tics, hindering its detection in serum or plasma. Because 
SAH is the product of all methylation reactions involving 
SAM as a methyl donor, an increased concentration of 
SAH in tissues is frequently accompanied by a decreased 
concentration of SAM. Therefore, the ratio of SAM to 
SAH is considered a more sensitive indicator than the 
concentration of either SAM or SAH alone, particularly 
when their changes are subtle during the early stages of 
dysfunction or under abnormal conditions. In this work, 
we established convenient immunoassays to measure the 
MI quickly without costly instrumentation.
The level of SAM varies with age and gender
Normal distribution of SAM and SAH levels in normal serum 
or plasma samples
Using the statistical methods in the R program, the 
distributions of SAM and SAH values among nor-
mal and diseased samples were calculated. Figure  6a 
shows the SAM and SAH values and distributions 
y = -2.2853x + 5.2678
R² = 0.9928
y = -2.1823x + 4.9984
R² = 0.9972
y = -2.2461x + 5.231
R² = 0.9987
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Fig. 5 Standard curves for the quantification of SAM (a) and SAH (b) 
by the direct cELISA. The x-axis shows the values of the base 10 loga-
rithm of the concentrations of the standards. The y-axis is expressed 
as the LOGIT, which is defined as Ln(A/AS0/(1 − A/AS0)), where A is 
the OD450 value of the standard and AS0 is the OD450 value of the 
control (without antigen). a HRP-118-6 was diluted 1:22,000, 1:25,000, 
1:30,000 and 1:32,000. The standard curve equations for the 3 differ-
ent diluted tests are shown in the figure. b Different lots of HRP-301-1 
and different dilutions were used. The standard curve equations for 
the 3 tests are shown
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from 81 normal serum samples. The average and SD 
was 386 nM ± 216.2 for SAM, 256.9 ± 150.7 for SAH, 
and 2.2 ± 1.9 for the MI. Figure 6b shows the SAM and 
SAH values and distributions from 291 serum samples. 
The results suggest normal distributions of SAM and 
SAH values from the subjects investigated. Therefore, 
Student’s t test was employed for statistical analysis. 
The distribution graph of diseased SAM levels also 
indicated that a significant number of patients had 
SAM values less than 300 nM. In contrast to the graph 
of the diseased SAH cases, the mean value of SAM did 
not represent the values of the majority of the samples, 
partially implying that many factors affect the SAM 
level.
Fig. 6 Distribution and values of SAM and SAH calculated using R programming. a 81 normal serum samples; b 291 diseased serum or plasma 
samples
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Distribution of normal plasma SAM levels in different genders 
and age groups
In another study of 310 plasma samples from the blood 
center, the ranges, averages, and standard deviations of 
SAM levels in females and males were analyzed, and the 
case numbers and percentages in each group are sum-
marized in Table 4. On average, women had higher SAM 
levels (296.92 nM) than men (232.86 nM). Furthermore, 
a larger percentage of females had SAM levels exceed-
ing 240 nM than males (Table 4; Fig. 6), contributing to 
the higher average SAM levels determined in females. 
Table  5 shows the different ranges of SAM levels by 
age group. With increasing age, the percentage of peo-
ple with SAM levels lower than 60  nM increased from 
1.46% among those aged 18–31  years to 12.5% among 
those aged 51–60  years. However, with increasing age, 
the percentage of people with SAM higher than 240 nM 
generally decreased, except in the age group from 51 
to 60 years. The decrease in SAM levels with age might 
be attributable to the following factors: too few cases 
in the 51- to 60-year-old age group; the 31- to 50-year-
old group is subject to higher life stress and the great-
est workload in China (a relatively larger percentage of 
people aged 31–50  years old were considered to have a 
sub-healthy condition, which might be related to lower 
SAM levels); a significant proportion of people aged 
51–60 years are retired and most likely find ways to take 
good care of their health and are under less stress. The 
results shown in Table 5 and Fig. 7 indicate that women 
have higher average SAM levels than men (approximately 
28% higher). This discrepancy is likely not due to dif-
ferences in diet, geographical area or social status. The 
fundamental reasons for these differences are unknown 
and are likely related to metabolism and genetic back-
ground. SAM levels were higher in females than in males, 
consistent with another study of 81 normal serum sam-
ples. The differences in SAM and SAH levels between 
the 310 plasma samples and 86 serum samples may be 
attributable to the prolonged period that the plasma was 
stored in the refrigerator before freezing.
Figure  7 shows the average SAM levels in different 
age and gender groups. In both genders, the SAM level 
continuously decreased with increasing age, indicat-
ing that SAM might be directly or indirectly involved in 
the aging process. Table  5 shows that a higher percent-
age of people older than 51 years had SAM levels of less 
than 60  nM, which indicates that older age was associ-
ated with decreased SAM levels. ANOVA analysis was 
performed with SAM, SAH and the MI as the response 
variables and age and gender groups as the explanatory 
variables. The p value was 0.0343 for the age group in 
terms of SAM (significant at level α = 0.05) and 0.0511 
for the gender group in terms of SAM (significant at level 
α = 0.1). These results indicate that the decreasing SAM 
trends for age and gender, as shown in Fig. 7, are statisti-
cally significant but at different levels. The levels of SAM 
in females were significantly higher than those in males. 
In a normal population, the younger a person, the higher 
the level of SAM. The SAM level was significantly higher 
in the 18- to 30-year-old age group than in any other age 
group older than 31 years. The SAM level in children and 
youth younger than 18 years was not evaluated.
A previous report indicated global DNA hypomethyla-
tion in older individuals compared with a younger popu-
lation. The data indicated that age-related variations in 
the global DNA methylation profile of leukocytes might 
be modulated by the daily intake of carbohydrates, lipids, 
vitamin B6, and magnesium and associated with serum 
protein levels. These nutritional factors may cause the 
SAM level to decrease greatly due to metabolic changes 
that occur as people age, contributing to the hypometh-
ylation observed in the elderly population.
Men and women have different hormone levels and 
considerably different hormone compositions, and thus 
their metabolisms differ. Liver cells express estrogen 
Table 4 Distribution of  normal human plasma SAM levels 
by gender
SAM (nM) Male no. (%) Female no. (%)
<30 0 0 1 1.01
30–60 9 4.2 3 3.03
60–120 44 20.85 9 9.09
120–240 70 33.18 33 33.33
240–480 75 35.55 39 39.39
480–960 13 6.16 14 14.14
>960 0 0 0 0
Avg. SAM 211 232.86 99 296.92



























Fig. 7 SAM levels in different age and gender groups. Data were 
obtained for 310 plasma samples from the blood center, which were 
obtained from 99 females and 211 males
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receptors that are related to development, lipid metab-
olism and insulin sensitivity, hepatic carcinogenesis, 
protection from drug-induced toxicity and fertility. 
In addition, estrogens can modulate growth hormone 
activity in the liver by acting centrally (pituitary growth 
hormone) and by modulating the GHR-JAK2-STAT5 
pathway [39]. Age and gender affect metabolic syn-
drome and metabolic disorders in all-cause and cardio-
vascular disease-related mortality [40]. The Met cycle 
may be related to the pathways indicated above, and fur-
ther investigations may elucidate the gender-dependent 
SAM level. A recent clinical trial assessing the efficacies 
of SAM for the treatment of depression in female and 
male patients indicated that gender might impact the 
antidepressant efficacy of SAM, with a greater therapeu-
tic effect observed in males [41] only. The average lower 
level of SAM in males than in females may contribute to 
the underlying mechanisms.
SAM and MI are reduced in disease
Cancers
Table 6 (after the Reference section) Study A shows the 
results of statistical analysis of data from cancer sam-
ples compared with normal serum samples by t-test. In 
liver cancers, SAH levels did not change significantly, 
and there was no significant change in the MI. By con-
trast, all other cancers exhibited a significant decrease in 
SAM levels and a significant increase in SAH levels, lead-
ing to more significant decreases in the MI, as indicated 
by the number of asterisks (*) for the t-test results. The 
dynamics of the levels of SAM and SAH in liver appear to 
differ from those in other tissues and organs. Our prior 
investigations using immunohistochemistry and flow 
cytometry to assess normal and malignant liver cell lines 
indicated that in cancer cells, both intracellular SAM and 
SAH are significantly reduced. Although this observation 
may only reflect SAM and SAH levels during a particular 
stage in each case of pathogenesis, it supports the unique 
characteristics of the MI in the liver compared to other 
tissues and organs, probably because SAM is primarily 
metabolized in the liver. The differences in SAH levels 
in liver cancers from other tissues or organs emphasize 
the importance of SAM measurements for describing the 
severity of liver disease.
Liver diseases
In a controlled study conducted at Xiangya Hospital, 
SAM levels were measured in patients with severe liver 
conditions such as acute viral hepatitis, cirrhosis, and liver 
failure. Patients who received SAM as a liver-protecting 
medicine were excluded from the study. We observed that 
SAM levels and the MI in different types of liver diseases, 
including hepatitis, carcinoma, cirrhosis and liver failure, 
were very different from those in the normal popula-
tion. These findings were striking. Patients with hepatitis 
were diagnosed with acute severe viral hepatitis (B and 
C). Patients with cirrhosis were also in an advanced stage 
requiring aggressive treatments in the hospital. Liver 
failure indicated that liver functions could no longer be 
compensated, and laboratory results revealed a severe 
loss of liver function. In hepatitis, 19.57% of the 46 sam-
ples had SAM levels higher than 120 nM, in contrast to 
95% of normal samples; 4.35% had SAM levels greater 
than 240  nM, in contrast to 69.14% of the normal sam-
ples; and 94.87% of the 46 samples had an MI less than 
0.5, in contrast to 8.64% of the normal samples. Among 
patients with hepatocyte carcinoma, 4 of 14 (28.57%) 
exhibited SAM levels greater than 120  nM, 7.14% had 
SAM levels greater than 240 nM, and 85.71% had an MI 
less than 0.5. Among patients with cirrhosis, 3 of 20 (15%) 
exhibited SAM levels greater than 120 nM, 5% had SAM 
levels greater than 240 nM, and 89.47% had an MI of less 
than 0.5. Finally, all 19 patients with liver failure had SAM 
levels less than 120 nM and an MI of less than 0.5. These 
Table 5 Distribution of normal human plasma SAM levels in different age groups
SAM (nM) Age 18–30 No. (%) Age 31–40 No. (%) Age 41–50 No. (%) Age 51–60 No. 
(%)
<30 1 0.73 0 0 0 0 0 0
30–60 1 0.73 5 6.10 4 5.33 2 12.50
60–120 17 12.41 16 19.51 17 22.67 3 18.75
120–240 42 30.66 28 34.15 30 40 3 18.75
240–480 58 42.34 28 34.15 20 26.67 8 50
480–960 18 13.14 5 6.10 4 5.33 0 0
>960 0 0 0 0 0 0 0 0
<60 2 1.46 5 6.10 4 5.33 2 12.5
>240 76 55.47 33 40.25 24 32 8 50
Total no. 137 82 75 16
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results demonstrate that SAM levels and MI values were 
significantly reduced compared with those in the normal 
controls; thus, SAM levels could be used as a biomarker 
to assist in the diagnosis of liver diseases.
Brain diseases
Table 7 presents the SAM and MI values of normal sub-
jects (two different studies) and 40 cases of brain disease. 
The percentages of cases with SAM levels greater than 
240 nM was lower among cases of cerebrovascular disease, 
Parkinson’s disease and depression compared with normal 
subjects. Moreover, among the cases of brain disease, there 
was a significant increase in the percentage of patients 
with an MI of less than 0.5 (8.64% of normal people with 
MI < 0.5 from one study versus 20% of Parkinson’s disease 
and depressed patients), and the percentage of patients 
with Parkinson’s disease and depression patients with an 
MI greater than 1 was significantly lower than the percent-
age of normal subjects with an MI greater than 1. These 
findings suggest that MI might be a good marker of Par-
kinson’s disease and depression, with a lower MI indicating 
a higher probability of Parkinson’s disease or depression. 
The results of the t-test analyses of SAM, SAH and MI 
between normal and brain disease are shown in Table  6 
Study B. The results demonstrated that SAM is decreased 
in cerebrovascular diseases, whereas the decrease in SAM 
in depression was not significant. However, the decreases 
in MI were very significant for all types of brain disease, 
suggesting that MI is a better biomarker for brain diseases.
Other diseases
Table 6 Study C shows the t-test results for other diseases 
versus normal serum controls. The decreases in SAM in 
cerebrovascular diseases, kidney diseases, chronic liver 
diseases, and respiratory diseases were not significant 
Table 6 Results of t test in diseases from different studies
Diseases Response 
variable
Mean p value Significance
Study A
 Liver cancer SAM 278.0652 0.03451 **
 Liver cancer SAH 293.35 0.3288
 Liver cancer MI 1.562109 0.1131
 Lung cancer SAM 262.5039 0.001248 ***
 Lung cancer SAH 326.9877 0.007807 ***
 Lung cancer MI 0.9710702 3.67E−06 ****
 Other cancer SAM 283.3233 0.00116 ***
 Other cancer SAH 394.7301 5.61E−06 ****







SAH 363.3671 0.03015 **
 Cerebrovascu-
lar diseases
MI 1.163449 2.03E−05 ****
 Depression SAM 337.385 0.3531
 Depression SAH 442.379 0.01176 **
 Depression MI 0.87051 4.81E−06 ****
 Parkinson’s 
disease
SAM 285.5726 0.07684 *
 Parkinson’s 
disease
SAH 794.5792 0.06972 *
 Parkinson’s 
disease







SAH 353.175 0.001237 ***
 Cerebrovascu-
lar diseases
MI 1.148035 2.31E−05 ****
 Diabetes SAM 262.3474 0.001136 ***
 Diabetes SAH 372.0686 0.003831 ***
 Diabetes MI 0.8619158 9.20E−08 ****
 High blood 
pressure
SAM 288.3645 0.0389 **
 High blood 
pressure
SAH 358.1118 0.01378 **
 High blood 
pressure
MI 0.9178064 3.93E−07 ****
 Heart diseases SAM 315.962 0.07938 **
 Heart diseases SAH 440.9451 5.95E−07 ****
 Heart diseases MI 0.7822701 5.61E−09 ****
 Inflammation SAM 223.732 3.05E−06 ****
 Inflammation SAH 292.012 0.2051
 Inflammation MI 0.8193137 1.91E−08 ****
 Kidney disease SAM 307.6073 0.1077
 Kidney disease SAH 497.1204 7.76E−06 ****




Mean p value Significance
 Chronic liver 
diseases
SAM 356.3407 0.5037
 Chronic liver 
diseases
SAH 444.0027 1.22E−06 ****
 Chronic liver 
diseases






SAH 486.5144 4.24E−08 ****
 Respiratory 
diseases
MI 0.7916811 5.27E−09 ****
* Represents significance at significance level = 0.1, ** represents significance at 
significance level = 0.05; *** represents significance at significance level = 0.01, 
**** represents significance at significance level = 0.001
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compared with the normal controls, whereas the 
increases in SAH in this diseases were significant. The 
levels of SAM decreased significantly in diabetes, high 
blood pressure, heart diseases and inflammation. How-
ever, the decreases in the MI were all extremely signifi-
cant for all analyzed diseases, which suggests that the MI 
is a better biomarker for these diseases.
SAM and inflammation
Interesting results were obtained for the levels of SAM, 
SAH and MI under conditions of inflammation (Table  6 
Study C). The levels of SAM were significantly reduced in 
inflammation conditions, whereas the increase in SAH in 
inflammation conditions was not significant. The diseases 
included in this inflammation group were mostly digestive, 
vascular and other benign inflammatory conditions. Com-
mon features of the group were chronic and widespread 
inflammatory responses. Thus, SAM appears to play a 
larger role in these conditions than SAH. This phenomenon 
is likely related to the important role of SAM in inflamma-
tory processes in which internal strong anti-inflammatory 
factors such as spermine or spermidine or MTA are gen-
erated as a result of SAM aminopropylation. Under certain 
pathological conditions, SAM aminopropylation might be 
blocked or deficient due to reduced SAM levels, result-
ing in defective anti-inflammatory functions of SAM and 
uncontrolled inflammatory reactions. Accordingly, sup-
plementation with SAM would, in most cases, control 
inflammation [42]. In North America, SAM pills are sold 
over-the-counter for the relief of joint pain or the treatment 
of osteoarthritis. The present study provided a foundation 
for the use of SAM for controlling inflammation.
Ranges of the MI
Table 8 summarizes the ranges and averages of the MI for 
all diseases in this study. The findings are consistent with 
the results of t-tests demonstrated that the MI is signifi-
cantly higher in normal subjects (average value of 2.23) 
than diseased patients (average of 0.87 or <1.56). This 
clear difference between the normal and diseased groups 
is also apparent for the maximum MI. The MI value was 
between 4 and 6 in cancer, and therefore the average MI 
in cancer was relatively higher than that in other diseased 
groups, primarily due to higher SAM levels in the in can-
cer samples. This result is consistent with an article by 
Greenberg et al. [43], who reported elevated serum SAM 
levels in patients with lung cancer compared with smok-
ers with benign lung disorders and healthy nonsmokers. 
No significant correlations were identified between SAM 
levels and tumor cell types, nodule size, or other demo-
graphic variables. The transient high SAM levels may be 
caused by the release of intracellular SAM from cells into 
the blood stream (as confirmed by IHC staining of SAM 
from cancer cells (data not shown) during certain stages of 
cancer progression). Thus, we observed wide ranges of MI 
values in all types of cancers. SAM release was significant 
only in certain stages of cancer development. The release 
of SAM into the blood stream at high levels contributes to 
the large ranges in SAM levels observed in all cancers. An 
MI of 5.67 was detected in only one of 68 cerebrovascu-
lar disease samples. All other MIs were less than 2.09. If 
that sample is considered an outlier, the average MI for this 
group is less than 1 rather than 1.06. Therefore, cerebro-
vascular diseases should be considered among other dis-
eases in evaluating the range and average value of the MI.
Table 7 SAM levels and MI values in brain diseases
Diseases (case #) % of SAM > 240 nM % of SAM > 120 nM % of MI > 2 % of MI > 1 % of MI < 0.5
Normal plasma (310) 90.36 96.79 6.95 42.47 16.98
Normal serum (81) 69.14 95.06 46.91 77.90 8.64
Cerebral hemorrhage (10), embolism (6), infarction (4) 85 90 0 65 0
Parkinson’s disease (10), depression (10) 70 90 0 25 20
Table 8 Ranges and averages of MI values in different dis-
eases
Group Range of MI Average MI
Normal 0.40–6.50 2.23
All diseases 0.07–5.67 0.87
Cerebrovascular diseases 0.36–5.67 1.06




Heart disease 0.07–1.95 0.78
Inflammation 0.28–2.13 0.82
Kidney disease 0.10–1.92 0.70
Liver diseases 0.22–2.50 0.89
Respiratory diseases 0.13–1.49 0.79
Other cancers 0.10–5.42 0.81
Liver cancer 0.13–4.98 1.56
Lung cancer 0.06–5.42 0.68
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SAM and the MI as disease biomarkers
If the antibodies used in the assays are specific, the MI 
measured by immunoassays carries greater weight than 
the MI measured based on free SAM and SAH alone. 
Because the free and complex forms of SAM and SAH 
are subject to enormous dynamics, a method that evalu-
ates the complete profiles has obvious advantages over 
simply examining one subset. SAM, SAH and the MI 
were previously used as biomarkers for diagnosing acute 
rejection after renal transplantation and nephrotoxicity 
events [44]. The present work and other studies investi-
gating Pneumocystis carinii pneumonia (PCP) in patients 
with HIV infection or other immunocompromised con-
ditions [45] suggest that the measurement of SAM lev-
els by cELISA could be an effective tool to diagnose the 
occurrence of PCP in immunocompromised conditions.
We evaluated SAM, SAH and MI levels in liver dis-
eases in three different scenarios: (a) hepatocyte can-
cers (Table 6 Study A), (b) acute or severe liver diseases 
described in the liver disease section above, and (c) 
chronic liver disorders (Table 6 Study C). The results from 
(b) indicate that SAM and the MI can be used to identify 
severe liver diseases based on the significant decreases in 
these parameters. The cutoff value could be set between 
120 nM and 240 nM. Because SAM is actively generated 
and metabolized in the liver, deterioration of liver func-
tion will significantly affect SAM metabolism. The results 
from (c) indicate that a non-significant decrease in SAM 
might be related to milder and chronic liver conditions 
in which SAM might be compensated as part of liver 
functional compensation over time. The results from (a) 
demonstrate a significant decrease in SAM in liver can-
cer patients but no significant increase in SAH levels, 
suggesting differences in the disruption of the Met cycle 
between carcinogenesis and other pathological processes. 
The level of SAM in hepatic carcinoma was decreased sig-
nificantly, in contrast to a report by Li [46]. The transient 
high levels of SAM were caused by the release of intracel-
lular SAM from cells into the bloodstream (confirmed by 
immunohistochemistry staining of SAM in cancer cells, 
data not shown) at some stage of cancer progression. 
Because SAM release is only significant in certain stages 
of cancer development, after this release is complete, the 
elevated SAM levels in the bloodstream will not be main-
tained, contributing to the large ranges of SAM levels 
observed for all cancer types Our samples were collected 
from various stages of cancers, and therefore wide ranges 
of MI values were observed in the cancer samples. Table 8 
also shows that the average MI for liver cancers was much 
higher than that for other diseases, indicating that in 
some liver cancers, the levels of SAM were high, which is 
consistent with Li’s report. In conclusion, SAM is a bio-
marker of the stages or severity of liver diseases.
Although we did not exhaustively examine all dis-
ease types, the cases observed in the present study were 
derived from a variety of diseases, although some dis-
eases were combined for analysis due to the small num-
ber of samples. The significant reduction of the observed 
in many disease types suggest that MI could serve as a 
useful biomarker for the evaluation of an individual’s 
health status. Furthermore, the diseased group exhib-
ited significantly lower SAM and MI levels and signifi-
cantly elevated SAH levels compared to healthy people. 
MI can thus serve as a health status indicator. We believe 
the major use of the MI as a health marker would involve 
monitoring changes in the MI of an individual over time. 
MI can be used as a screening biomarker to detect an 
unfavorable health condition in humans, although fur-
ther examinations are warranted for a final disease diag-
nosis. Further clinical investigations in different races and 
segments of the population stratified by age, gender, diet, 
medication or even genetic background are needed. The 
MI will likely be useful for aiding the detection of dis-
ease conditions in healthy populations and be included in 
annual health examination panels.
Conclusions
In the present study, monoclonal antibodies against SAM 
and SAH were characterized, and associated immuno-
assays were established. This preliminary investigation 
indicated that SAM, SAH and MI are good indicators of 
general health. In the absence of factors that may alter 
the value of the MI, such as special diets and medica-
tions, a significant reduction of the MI compared with 
an individual’s baseline MI reference profile may suggest 
unfavorable conditions or diseases and warrant a visit to 
the doctor.
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